Valrelease Alternatives Compared
| Valrelease (diazepam) | Xcopri (cenobamate) | Keppra (levetiracetam) |
|
|---|
| Valrelease (diazepam) | Xcopri (cenobamate) | Keppra (levetiracetam) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Anxiety, Hyperekplexia, Endoscopy or Radiology Premedication, Alcohol Withdrawal, Seizures, ICU Agitation, Light Anesthesia, Light Sedation, Muscle Spasm, Night Terrors, Seizure... View more |
Prescription only
Xcopri is a brand name for cenobamate which may be used to reduce the frequency of partial seizures in adults. In some people, it reduces the frequency to zero. Clumsiness, dizziness, drowsiness... View more |
Prescription only
Keppra is an anticonvulsant that is used in conjunction with other medications for the treatment of certain types of seizures. It may cause drowsiness but it is less likely than some other... View more |
Related suggestions |
|||||||||||||||
| More about (diazepam) | More about Xcopri (cenobamate) | More about Keppra (levetiracetam) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Valrelease has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Xcopri has an average rating of 8.1 out of 10 from a total of 43 ratings on Drugs.com. 72% of reviewers reported a positive effect, while 5% reported a negative effect. |
Keppra has an average rating of 5.7 out of 10 from a total of 310 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 34% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Valrelease side effects |
View all Xcopri side effects |
View all Keppra side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
| Lower cost generic approved | ||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Xcopri prices |
View all Keppra prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other diazepam brands include: Diastat, Diastat AcuDial, Diastat Pediatric, Diazepam Intensol, Libervant, Valium, Valtoco |
N/A |
Other levetiracetam brands include: Elepsia XR, Keppra XR, Roweepra, Roweepra XR, Spritam | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
70 hours |
60 hours |
8 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
Some potential for abuse
Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 526 drugs are known to interact with Valrelease:
|
A total of 584 drugs are known to interact with Xcopri:
|
A total of 239 drugs are known to interact with Keppra:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
November 21, 2019 |
November 30, 1999 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.